Cargando…
Plitidepsin Has a Safe Cardiac Profile: A Comprehensive Analysis
Plitidepsin is a cyclic depsipeptide of marine origin in clinical development in cancer patients. Previously, some depsipeptides have been linked to increased cardiac toxicity. Clinical databases were searched for cardiac adverse events (CAEs) that occurred in clinical trials with the single-agent p...
Autores principales: | Soto-Matos, Arturo, Szyldergemajn, Sergio, Extremera, Sonia, Miguel-Lillo, Bernardo, Alfaro, Vicente, Coronado, Cinthya, Lardelli, Pilar, Roy, Elena, Corrado, Claudia Silvia, Kahatt, Carmen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Molecular Diversity Preservation International
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3131558/ https://www.ncbi.nlm.nih.gov/pubmed/21747745 http://dx.doi.org/10.3390/md9061007 |
Ejemplares similares
-
Phase I–II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma
por: Plummer, R, et al.
Publicado: (2013) -
Phase II Study of Biweekly Plitidepsin as Second-Line Therapy for Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium
por: Dumez, Herlinde, et al.
Publicado: (2009) -
A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin
por: Grosso, Federica, et al.
Publicado: (2012) -
Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma
por: Spicka, Ivan, et al.
Publicado: (2019) -
Plitidepsin for multiple myeloma
Publicado: (2019)